Sun Pharma Ordered to Halt Eye-Care Drug Output at Plant
India has ordered Sun Pharma to stop producing eye-care drugs at one of its plants after quality lapses were found. The order means production at that site must stop, affecting the company's supply of these medicines. The move comes as India's drug quality standards face closer scrutiny at home and overseas.
Context
Context: Indian cough syrups were linked to child deaths in Gambia and Uzbekistan in 2022, which pushed regulators to tighten checks on locally made medicines. Quality lapses at a drug plant are taken seriously because they can affect patients who rely on the product.
Burning Potato score: 87%